License and Collaboration Arrangements (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenue	$ 67,259	$ 67,257	$ 224,623	$ 265,536
Zai Lab | Research and Development Support
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	91,000		91,000
License revenue recognized			3
PAION AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	109,500		109,500
PAION AG | Cost Reimbursement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	1,000		1,000
Everest Medicines Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	900		1,600
Sales milestone payments receivable	20,000		20,000
License revenue recognized			$ 8,000
Royalties payable period after first commercial sale of product			10 years
Everest Medicines Limited | Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursed for direct and certain indirect manufacturing costs			110.00%
George Washington University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			6.00%
Percentage of royalty on payments received from sublicensees			15.00%
Obligation to pay royalties	$ 500		$ 1,700
Harvard University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			5.00%
Percentage of royalty on payments received from sublicensees			20.00%
Cost of license revenue			$ 1,600
Clinical development and regulatory milestones amount payable			$ 15,100
Percentage of minimum royalty rate			4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds			7.50%
Paratek Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			2.25%
Claim expiration			2023-10